Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Summary
Third Opinion Trial Synopsis:
This study is testing a new treatment called bb2121 for people with a type of cancer called multiple myeloma that has come back or is not responding to other treatments. The treatment will be tested on about 381 people, with about 254 people receiving bb2121 and 127 people receiving a standard treatment. The study will look at how well the treatment works and how safe it is.
This study is testing a new treatment called bb2121 for people with a type of cancer called multiple myeloma that has come back or is not responding to other treatments. The treatment will be tested on about 381 people, with about 254 people receiving bb2121 and 127 people receiving a standard treatment. The study will look at how well the treatment works and how safe it is.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.